Prevalence of Atelectasis in Critical Trauma Patients

The Prevalence and Risk Factors for Lung Atelectasis in Patients With Critical Trauma Who Are Intubated and Mechanically Ventilated

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02739854

Enrollment

338

Registered

2016-04-15

Start date

2016-04-30

Completion date

2017-05-31

Last updated

2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Atelectasis

Keywords

trauma, atelectasis

Brief summary

The purpose of this study is to identify the prevalence rate and risk factors for pulmonary complications in patients with critical trauma who intubated and mechanical ventilation.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* An inclusion criterion is the traumatic patients (e.g. head injury, blunt chest, blunt abdomen, and fracture of spine; with or without operative, pure or multitrauma) with intubation and mechanical ventilation who admit at this time period will recruit to the study.

Exclusion criteria

* a patients who admit less than 1 day will be excluded such as sudden death or moving to other ward because of improving conditions, etc.

Design outcomes

Primary

Measure	Time frame
number of participants with pulmonary atelectasis	from the date of randomization until the date of first documented of atelectasis, assessed up to 1 years

Secondary

Measure	Time frame	Description
number of participants with pneumonia	from the date of randomization until the date of first documented of pneumonia, assessed up to 1 years	—
number of participants with pleural effusion	from the date of randomization until the date of first documented of pleural effusion, assessed up to 1 years	—
number of participants with abnormal laboratory values	from the date of randomization until the date of first documented of pleural effusion, assessed up to 1 years	the laboratory test include arterial blood gases (ABG), Clinical chemistry test (i.e. Blood urea nitrogen, Creatinine, Sodium, Potassium, Phosphorus, Chloride, Magnesium).
number of participants with adverse events that are related to treatment	from the date of randomization until the date of first documented of pleural effusion, assessed up to 1 years	These data are collected from medical records (i.e. arrhythmia, hypoxia)

Countries

Thailand

Outcome results